Acute migraine treatment has long been dominated by triptans and NSAIDs, which are effective for many patients but carry limitations—cardiovascular contraindications for triptans, gastrointestinal side effects for NSAIDs, and inconsistent response. Gepants, the oral small-molecule class of CGRP antagonists, are transforming acute treatment by offering an alternative with a favorable tolerability profile and fewer cardiovascular restrictions.

Tolerability and Patient Selection

The primary transformation is tolerability. Gepants are associated with lower rates of the side effects that lead patients to discontinue triptans, and they lack the vasoconstrictive mechanism that contraindicates triptans in patients with cardiovascular risk . This opens acute treatment to a population that previously had limited options, and it improves adherence among patients who tolerated triptans poorly.

Expanding the Acute Treatment Arsenal

A second transformation is choice. With multiple gepants approved for acute use, clinicians can tailor treatment based on patient response, prior therapy history, and comorbidities. This diversification supports the broader shift toward personalized migraine care and drives prescription volume growth within the CGRP class.

People Also Ask

How do gepants differ from triptans?
Gepants are oral CGRP antagonists that lack triptans' vasoconstrictive mechanism, making them suitable for some patients with cardiovascular risk who cannot use triptans.

Are gepants used for prevention as well?
Some gepants are approved for both acute and preventive migraine treatment, expanding their clinical utility.

As gepants continue to gain traction, they will reshape acute migraine treatment and contribute to the growth of the CGRP antagonist market.

Tags: #Gepants #AcuteMigraine #CGRPAntagonists #MigraineTreatment #Neurology